The company's allogeneic stem cell technology platform for the treatment of osteoarthritis (OA) and other inflammatory conditions is called Progenza. Results of the phase 1 STEP trial (Safety, Tolerability and Efficacy of Progenza) were published in the Journal of Translational Medicine in 2018.
The study showed that a single injection of Progenza, which are cells, into the knee was safe and well tolerated by patients the treatment was shown to have durable and clinically meaningful pain relief in patients with knee OA. A statistically significant improvement in lateral tibial cartilage volume for patients treated with 3.9 million cells of Progenza was shown by MRI compared to a worsening of the condition in placebo patients (p=0.028).
Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions. Progenza cells reduce inflammation and pain and encourage accelerated healing and repair through secretion of cytokines, growth factors and exosomes.
Progenza is produced from expanded mesenchymal stem cells (MSCs) extracted from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from MSCs that improve viability and functionality of the cells during the freezing and thawing process. Regeneus has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone.
Progenza is manufactured using adipose-derived MSCs and are expanded through the company's proprietary and scalable manufacturing process which has the capacity to produce millions of therapeutic doses of Progenza from a single donor.
Regeneus was founded.
Dr Charlotte Morgan
Head of R&D
Dr Duncan Thomson
VP Licensing and Alliances
Clinical Research Director
Professor Graham Vesey
Chief Scientific Officer
Regeneus close to finalising first clinical partnership for its lead cell therapy in Japan
Regeneus receives Chinese patent for biomarkers in monitoring disease progression for stem cell therapy
Tim Boreham: What's next for stem cell play Regeneus as it waits for Japan deal
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- MSC (Mesenchymal Stromal Cell)The term MSC is referred to in scientific literature as mesenchymal stem cell, mesenchymal stromal cell, marrow stromal cell or multipotent mesenchymal stromal cell. Most MSCs are isolated from bone marrow and adipose tissue but have also been identified in other sources such as umbilical cord.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.